戻る
Supernus Pharmaceuticals Inc (SUPN)価格
SUPN 株価推移チャート
SUPN 財務
Supernus Pharmaceuticals Inc
$50.84
1.98%
$0.99
終値： Feb 13, 16:00:00 GMT-5
$50.84
0%
$0
アフターマーケット：Feb 13, 20:00:00 GMT-5
収入
貸借対照表
現金の流れ
年次
四半期
SUPN 収入
金額は百万米ドル単位。会計年度は2月から1月まで。
Follow-Up Questions
Supernus Pharmaceuticals Incの主要な財務諸表は何ですか？
SUPNの主要な財務比率は何ですか？
Supernus Pharmaceuticals Incの収益はセグメントまたは地域別にどのように分けられていますか？
Supernus Pharmaceuticals Incは収益を上げていますか？
Supernus Pharmaceuticals Incに負債はありますか？
Supernus Pharmaceuticals Incの発行済株式数は何株ですか？
主要データ
前終値
$49.85
始値
$49.71
当日レンジ
$49.46 - $51.4
52週レンジ
$29.16 - $57.65
取引高
681.3K
平均取引高
671.1K
1株当たり利益(TTM)
-0.34
配当利回り
--
時価総額
$2.9B
SUPNとは何ですか？
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 674 full-time employees. The company went IPO on 2010-12-28. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. The company also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.